These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1280 related items for PubMed ID: 19558252

  • 21. Botulinum toxin type A (BOTOX) for treatment of migraine.
    Binder WJ, Brin MF, Blitzer A, Pogoda JM.
    Semin Cutan Med Surg; 2001 Jun; 20(2):93-100. PubMed ID: 11474749
    [Abstract] [Full Text] [Related]

  • 22. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches.
    Troost BT.
    Expert Rev Neurother; 2004 Jan; 4(1):27-31. PubMed ID: 15853612
    [Abstract] [Full Text] [Related]

  • 23. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM, Schim JD, Chippendale TJ.
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [Abstract] [Full Text] [Related]

  • 24. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT, Kailasam J, Meadors L.
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [Abstract] [Full Text] [Related]

  • 25. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
    Brandes JL, Visser WH, Farmer MV, Schuhl AL, Malbecq W, Vrijens F, Lines CR, Reines SA, Protocol 125 study group.
    Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
    [Abstract] [Full Text] [Related]

  • 26. Treatment of tension-type headache with botox: a review of the literature.
    Rozen D, Sharma J.
    Mt Sinai J Med; 2006 Jan; 73(1):493-8. PubMed ID: 16470328
    [Abstract] [Full Text] [Related]

  • 27. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024-026-036 Study Group.
    J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
    [Abstract] [Full Text] [Related]

  • 28. Botulinum toxins for the prevention of migraine in adults.
    Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A.
    Cochrane Database Syst Rev; 2018 Jun 25; 6(6):CD011616. PubMed ID: 29939406
    [Abstract] [Full Text] [Related]

  • 29. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
    Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG, Tonabersat TON-01-05 Study Group.
    Cephalalgia; 2009 Jul 25; 29(7):742-50. PubMed ID: 19222510
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
    Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W.
    Arch Dermatol; 2006 Mar 25; 142(3):320-6. PubMed ID: 16549707
    [Abstract] [Full Text] [Related]

  • 31. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial.
    Donaldson D, Sundermann R, Jackson R, Bastani A.
    Am J Emerg Med; 2008 Feb 25; 26(2):124-30. PubMed ID: 18272089
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
    Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP, Study Group.
    Headache; 2009 Feb 25; 49(2):216-26. PubMed ID: 19222595
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL.
    Mov Disord; 2005 Jul 25; 20(7):783-91. PubMed ID: 15736159
    [Abstract] [Full Text] [Related]

  • 34. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY, North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group.
    J Am Acad Dermatol; 2007 Apr 25; 56(4):604-11. PubMed ID: 17306417
    [Abstract] [Full Text] [Related]

  • 35. Treatment of migraine headache with botulinum toxin type A.
    Binder WJ, Blitzer A.
    Facial Plast Surg Clin North Am; 2003 Nov 25; 11(4):465-75. PubMed ID: 15062251
    [Abstract] [Full Text] [Related]

  • 36. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
    Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B.
    Plast Reconstr Surg; 2019 Jan 25; 143(1):239-250. PubMed ID: 30589800
    [Abstract] [Full Text] [Related]

  • 37. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
    Dodick D, Blumenfeld A, Silberstein SD.
    Clin Dermatol; 2004 Jan 25; 22(1):76-81. PubMed ID: 15158549
    [Abstract] [Full Text] [Related]

  • 38. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity.
    Suputtitada A, Suwanwela NC.
    Disabil Rehabil; 2005 Feb 18; 27(4):176-84. PubMed ID: 15824048
    [Abstract] [Full Text] [Related]

  • 39. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study.
    Smuts JA, Schultz D, Barnard A.
    Headache; 2004 Sep 18; 44(8):801-5. PubMed ID: 15330827
    [Abstract] [Full Text] [Related]

  • 40. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.
    Carroll A, Barnes M, Comiskey C.
    Clin Rehabil; 2008 Jun 18; 22(6):513-9. PubMed ID: 18511531
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 64.